Designer Diagnostics Engages U.S. Commercial Service for International Growth.BOCA RATON Boca Raton (bō`kə rətōn`), city (1990 pop. 61,492), Palm Beach co., SE Fla., on the Atlantic; inc. 1925. Boca Raton is a popular resort and retirement community that experienced significant industrial development in the 1970s and 80s. , Fla. -- Nutra Pharma Corp. (OTCBB OTCBB See OTC Bulletin Board (OTCBB). : NPHC NPHC National Pan Hellenic Council NPHC North Phoenix Heart Center ), a biotechnology company that is developing drugs for HIV HIV (Human Immunodeficiency Virus), either of two closely related retroviruses that invade T-helper lymphocytes and are responsible for AIDS. There are two types of HIV: HIV-1 and HIV-2. HIV-1 is responsible for the vast majority of AIDS in the United States. and Multiple Sclerosis has today announced that its medical device subsidiary, Designer Diagnostics, has initiated a partnership with the U.S. Commercial Service to help build international sales of its diagnostic test kits. "Partnering with the U.S. Commercial Service provides Designer Diagnostics with an incredible opportunity to build key relationships with international buyers of medical diagnostic equipment," explained Neil Roth, President of Designer Diagnostics, Inc. "We will begin by focusing on geographic regions in Africa and South Asia This article is about the geopolitical region in Asia. For geophysical treatments, see Indian subcontinent. South Asia, also known as Southern Asia where Tuberculosis and NonTuberculosis Mycobacterium mycobacterium Any of the rod-shaped bacteria that make up the genus Mycobacterium. The two most important species cause tuberculosis and leprosy in humans; another species causes tuberculosis in both cattle and humans. have a higher level of occurrence," he added. The U.S. Commercial Service is a division of the U.S. Department of Commerce and is designed to provide American businesses with international market research data and introductions to international buyers and distributors. The Organization has offices in over 107 U.S. cities and in 145 U.S. Embassies and Consulates worldwide. "This partnership will provide Designer Diagnostics with access to a group of international buyers that understand the significance of our improved test kit technology," commented Rik J. Deitsch, Chairman and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of Nutra Pharma Corporation. "Not only are the Designer Diagnostics test kits faster, but they are also more cost effective compared to all other traditional methods. Additionally, they can be used in the field and stored in hostile environments, requiring no special handling or refrigeration refrigeration, process for drawing heat from substances to lower their temperature, often for purposes of preservation. Refrigeration in its modern, portable form also depends on insulating materials that are thin yet effective. ," he concluded. In January, Designer Diagnostics announced the positive results of an in-vitro analysis of its Tuberculosis (TB) test kit. Normal culturing methods can take as long as 10 weeks to produce results, whereas Designer Diagnostics test kits showed similar results within 10 days. About Nutra Pharma Corp. Nutra Pharma Corp. is a biopharmaceutical company specializing in the acquisition, licensing and commercialization of pharmaceutical products and technologies for the management of neurological disorders This is a list of major and frequently observed neurological disorders (e.g. Alzheimer's disease), symptoms (e.g.back pain), signs (e.g. aphasia) and syndromes (e.g. Aicardi syndrome). , cancer, autoimmune and infectious diseases infectious diseases: see communicable diseases. . Nutra Pharma Corp. through its subsidiaries carries out basic drug discovery research and clinical development and also seeks strategic licensing partnerships to reduce the risks associated with the drug development process. The Company's holding, ReceptoPharm, Inc, is developing technologies for the production of drugs for HIV and Multiple Sclerosis ("MS"). The Company's subsidiary, Designer Diagnostics is engaged in the research and development of diagnostic test kits designed to be used for the rapid identification of infectious diseases such as Tuberculosis (TB) and Mycobacterium avium-intracellulare (MAI MAI Mail (File Name Extension) MAI Multilateral Agreement on Investment MAI Maius (Latin: May) MAI Ministerul Administratiei si Internelor (Romanian) ). Nutra Pharma continues to identify and acquire intellectual property and companies in the biotechnology arena. http://www.NutraPharma.com http://www.DesignerDiagnostics.com This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The Company's business is subject to various risks, which are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). The partnership with the U.S. Commercial Service should not be construed as an indication in any way whatsoever of the value of the Company or its common stock. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion